Last reviewed · How we verify
Vaginal tablet Endometrin twice a day
At a glance
| Generic name | Vaginal tablet Endometrin twice a day |
|---|---|
| Also known as | Endometrin 100 mg twice a day |
| Sponsor | Wolfson Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Oral Versus Vaginal Progesterone for Luteal Phase Supplementation in Frozen Embryo Transfer Cycles (PHASE4)
- Luteal Phase Progesterone in IUI and Gonadotropin Cycles (PHASE3)
- Effects of E2, P4 and LH Levels on the Day of Transfer and Endometrial Cavity Thickness on Implantation Success in Patients With Frozen-thawed Embryo Transfer Cycle (NA)
- Luteal Support in Frozen-Thawed Embryo Transfer Cycles (PHASE4)
- Evaluation of Different Luteal Phase Support Methods in Patients With Poor Ovarian Response (PHASE3)
- Vaginal Compared to Intramuscular Progesterone for Frozen Embryo Transfer (PHASE4)
- Progesterone and Doppler in Recurrent Abortion (PHASE4)
- The Need for Luteal Support in NC-FET (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vaginal tablet Endometrin twice a day CI brief — competitive landscape report
- Vaginal tablet Endometrin twice a day updates RSS · CI watch RSS
- Wolfson Medical Center portfolio CI